A Rocky First Quarter For Big Pharma Stocks

 
• By Joseph Haas

Big pharma stocks, with few exceptions, saw big declines in valuation in the quarter amid the COVID-19 stock market rollercoaster, but pharma outperformed the S&P 500, showing the industry's resiliency in a global health crisis.

Values decline of oil
Twelve of 13 big pharmas reviewed have suffered valuation declines over the first quarter

More from COVID-19

More from Scrip